BACKGROUND: Antitachycardia pacing (ATP) fails to terminate 5% to 25% of ventricular
tachycardias (VTs) occurring in implantable cardioverter-defibrillator patients. We …

The purpose of this study was to determine the termination and acceleration rates for 1 to 6
attempts of antitachycardia pacing (ATP) delivered by ICD in order to terminate …

Background: Despite the wide use of antitachycardia pacing (ATP) in patients with
implantable cardioverter defibrillators (ICDs), predictors of ATP success remain poorly …

Purpose Antitachycardia pacing (ATP) terminates the majority (but not all) of slow ventricular
tachycardias (S-VT) with a cycle length (CL)> 320 ms. Usually, several ATP therapies are …

Introduction Ventricular tachycardia (VT) acceleration due to antitachycardia pacing (ATP)
therapy could be often observed in patients with implantable cardioverter defibrillator (ICD) …

The incorporation of antitachycardia pacing (ATP) into implantable cardioverter defibrillators
(ICDs) has provided a better tolerated alternative to shocks. ATP has been shown to be …

Introduction: Antitachycardia pacing (ATP) effectively treats monomorphic ventricular
tachycardia (VT). The VT may cease immediately upon ATP completion (type‐1 break), or it …

Background Antitachycardia pacing (ATP) provides safe and painless termination of
reentrant ventricular arrhythmias in patients with implantable cardioverter defibrillator (ICDs) …

Background—Implantable cardioverter-defibrillators (ICDs) reduce the risk of sudden
cardiac death. The objective of this study was to evaluate whether testing of antitachycardia …

Background Antitachycardia pacing (ATP) is an established implantable cardioverter-
defibrillator (ICD) therapy that terminates ventricular tachycardias (VTs) without painful ICD …